Atara Biotherapeutics, Inc. (ATRA) company profile

Atara Biotherapeutics is a biotechnology company that develops allogeneic T-cell immunotherapies for patients with serious cancers and autoimmune conditions. The company utilizes an Epstein-Barr virus T-cell platform to create off-the-shelf cellular treatments manufactured from donor cells. Its lead product is tabelecleucel, marketed as Ebvallo, an immunotherapy indicated for patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease. Atara licenses and commercializes this therapy through a partnership with Pierre Fabre Medicament, serving immunocompromised patients who have undergone solid organ or stem cell transplants and failed conventional treatments.

The company maintains its principal executive offices in Thousand Oaks, California. Its approved therapy holds commercial marketing authorizations in the European Economic Area, the United Kingdom, and Switzerland, while its late-stage clinical trials include participating sites across the United States, Europe, and Canada. Atara coordinates with external corporate partners and third-party contract manufacturers to manage the production and distribution of its cellular therapies.

Summary of the business section of Atara Biotherapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price per share is $11.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 14 employees.”